CureVac ties up Wacker to churn out more than 100M doses of mRNA coronavirus vaccine

Riding a wave of interest in mRNA-based vaccines, Germany's CureVac is looking to rapidly drive manufacturing of its own shot candidate. After announcing a plan to bring more partners on board, CureVac has knotted the first of those deals to the tune of 100 million doses. CureVac has tagged German chemical company Wacker to churn out drug substance for its mRNA-based COVID-19 vaccine with the goal of adding 100 million doses per year to the biotech's stockpile, the partners said this week. Wacker will produce those doses at its Amsterdam facility starting in the first half of 2021, the companies said. The firm plans to 'ramp up' its manufacturing capacity to meet that demand and is prepared to expand in the future to add more doses.